Hydrogen Sulfide (H2S) Donor Therapy for Neurodegeneration

Hydrogen sulfide (H2S), an endogenous gasotransmitter, plays crucial roles in neuroprotection through antioxidant, anti-inflammatory, and anti-apoptotic mechanisms. H2S donor therapy represents a novel approach to restore deficient gasotransmitter signaling in Alzheimer's disease (AD), Parkinson's disease (PD), ALS, and other neurodegenerative conditions.

Score Summary (10-Dimension Rubric)

Total Score: 76/100

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 8 | Novel gasotransmitter class; distinct from existing antioxidant/anti-inflammatory approaches |
| Mechanistic Rationale | 9 | Strong preclinical data; addresses mitochondrial dysfunction, oxidative stress, neuroinflammation |
| Root-Cause Coverage | 7 | Targets endogenous signaling deficiency; upstream of multiple pathologies |
| Delivery Feasibility | 7 | H2S donors with controlled release available; oral administration feasible |
| Safety Plausibility | 8 | H2S is endogenous; physiological concentrations are well-tolerated |
| Combinability | 9 | Strong synergy with antioxidants, mitochondrial protectants, anti-inflammatory agents |
| Biomarker Availability | 7 | H2S levels measurable in blood/CSF; enzyme activity can be monitored |
| De-risking Path | 7 | Multiple H2S donors in clinical pipeline for other conditions |
| Multi-disease Potential | 9 | Preclinical efficacy across AD, PD, ALS, HD |
| Patient Impact | 7 | Addresses fundamental signaling deficits; broad applicability |

Biological Rationale

H2S Signaling in the Brain

Hydrogen sulfide (H2S), an endogenous gasotransmitter, plays crucial roles in neuroprotection through antioxidant, anti-inflammatory, and anti-apoptotic mechanisms. H2S donor therapy represents a novel approach to restore deficient gasotransmitter signaling in Alzheimer's disease (AD), Parkinson's disease (PD), ALS, and other neurodegenerative conditions.

Score Summary (10-Dimension Rubric)

Total Score: 76/100

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 8 | Novel gasotransmitter class; distinct from existing antioxidant/anti-inflammatory approaches |
| Mechanistic Rationale | 9 | Strong preclinical data; addresses mitochondrial dysfunction, oxidative stress, neuroinflammation |
| Root-Cause Coverage | 7 | Targets endogenous signaling deficiency; upstream of multiple pathologies |
| Delivery Feasibility | 7 | H2S donors with controlled release available; oral administration feasible |
| Safety Plausibility | 8 | H2S is endogenous; physiological concentrations are well-tolerated |
| Combinability | 9 | Strong synergy with antioxidants, mitochondrial protectants, anti-inflammatory agents |
| Biomarker Availability | 7 | H2S levels measurable in blood/CSF; enzyme activity can be monitored |
| De-risking Path | 7 | Multiple H2S donors in clinical pipeline for other conditions |
| Multi-disease Potential | 9 | Preclinical efficacy across AD, PD, ALS, HD |
| Patient Impact | 7 | Addresses fundamental signaling deficits; broad applicability |

Biological Rationale

H2S Signaling in the Brain

Hydrogen sulfide is produced endogenously through the transsulfuration pathway primarily by:

• Cystathionine β-synthase (CBS): Major H2S-producing enzyme in the brain
• Cystathionine γ-lyase (CSE): Secondary H2S producer
• 3-mercaptopyruvate sulfurtransferase (3-MST): Mitochondrial H2S production

H2S Deficiency in Neurodegeneration

Multiple lines of evidence demonstrate H2S deficiency in neurodegenerative diseases:

| Disease | Finding | Reference |
|---------|---------|-----------|
| AD | CBS expression reduced in AD brain; H2S levels decreased | Kumar 2020 |
| PD | CSE activity reduced in substantia nigra; plasma H2S low | Tang 2023 |
| ALS | CBS deficiency drives neuroinflammation | Chen 2024 |
| HD | Cystathionine β-synthase deficiency | Chen 2024 |

Mechanisms of Neuroprotection

Therapeutic Approach

H2S Donor Compounds

Several H2S donors are available with controlled-release properties:

| Compound | Mechanism | Development Stage | Notes |
|----------|-----------|-------------------|-------|
| NaHS | H2S gas release | Preclinical | Fast release, limited utility |
| GYY4137 | Slow H2S release | Preclinical | Stable, controlled release |
| AP39 | Mitochondria-targeted | Research | Selective mitochondrial delivery |
| ACOS-1 | CBS activator | Research | Enhances endogenous H2S |
| S-propargyl-cysteine (SPRC) | H2S donor | Preclinical | Neuroprotective |
| Sodium hydrosulfide (NaHS) | H2S donor | Preclinical in neurodegeneration | Improves mitochondrial function |

Delivery Strategy

Primary approach: GYY4137-type slow-release H2S donors

• Dosing: 50-200 mg/kg/day (preclinical)
• Route: Oral or intraperitoneal
• Duration: Chronic administration

Endogenous enhancement: CBS/CSE activators (ACOS-1)

Disease-Specific Rationale

Alzheimer's Disease

• Reduces Aβ-induced oxidative stress
• Inhibits tau hyperphosphorylation
• Preserves mitochondrial function
• Reduces neuroinflammation
• Reference: Yang 2021 showed cognitive improvement in 5xFAD mice

Parkinson's Disease

• Protects dopaminergic neurons
• Reduces α-synuclein aggregation
• Improves mitochondrial Complex I activity
• Reference: Tang 2023 demonstrated neuroprotection in MPTP model

Amyotrophic Lateral Sclerosis

• Addresses CBS deficiency-driven neuroinflammation
• Improves mitochondrial function
• Reference: Zhao 2024 showed improved mitochondrial function in ALS models

Huntington's Disease

• Addresses CBS deficiency
• Reduces mutant huntingtin toxicity
• Reference: Chen 2024 demonstrated cystathionine β-synthase deficiency in HD

Combination Strategies

H2S donors show strong synergy with:

| Combination | Rationale | Expected Synergy |
|-------------|-----------|------------------|
| NRF2 activators | Complementary antioxidant pathways | High |
| Mitochondrial protectants | Enhanced mitochondrial function | High |
| Anti-inflammatory agents | Multi-target neuroinflammation | High |
| Anti-amyloid approaches | Reduced oxidative stress | Moderate |
| Autophagy inducers | Enhanced protein clearance | Moderate |

De-risking Path

Preclinical Requirements

Clinical Translation

Biomarkers for Clinical Trials

• H2S levels: Plasma and CSF H2S measurement
• Oxidative stress markers: 8-OHdG, isoprostanes
• Inflammatory markers: IL-6, TNF-α, GFAP
• Clinical endpoints: Cognitive testing (ADAS-Cog), motor testing (UPDRS)

Risks and Mitigation

| Risk | Likelihood | Mitigation |
|------|------------|-------------|
| Off-target effects | Moderate | Controlled-release donors |
| H2S toxicity at high doses | Low | Dose-finding studies |
| Limited BBB penetration | Moderate | Mitochondria-targeted donors |
| Variable patient response | Moderate | Biomarker stratification |

Disease Coverage

| Disease | Coverage Score | Rationale |
|---------|-----------------|-----------|
| Alzheimer's | 8 | Strong preclinical, multiple mechanisms |
| Parkinson's | 8 | Direct evidence in PD models |
| ALS | 7 | Emerging evidence |
| FTD | 6 | Preclinical data emerging |
| HD | 7 | CBS deficiency evidence |
| Aging | 8 | Addresses age-related decline |

Implementation Roadmap

Month 1-3: Preclinical

• Dose-ranging in mouse AD model (5xFAD)
• Biodistribution studies
• GLP toxicology initiation

Month 4-6: Preclinical

• Complete GLP toxicology
• PD model studies
• Combination studies

Month 7-12: Clinical

• IND-enabling studies
• Phase I protocol development
• Patient stratification biomarker validation

Year 2: Clinical

• Phase I trial initiation
• Phase II site preparation
• Biomarker assay validation

Conclusion

H2S donor therapy represents a promising novel approach for neurodegeneration with strong mechanistic rationale and growing preclinical evidence. The therapy addresses multiple core pathologies through antioxidant, anti-inflammatory, and mitochondrial protective mechanisms. GYY4137-type slow-release donors provide a manageable safety profile, and biomarkers are available for patient selection and response monitoring. The multi-disease potential and combination synergy further strengthen the approach's therapeutic value.

Cross-Links

Related Mechanisms

• [Hydrogen Sulfide Signaling in Neurodegeneration](/mechanisms/hydrogen-sulfide-signaling-neurodegeneration)
• [Mitochondrial Dysfunction in Neurodegeneration](/mechanisms/mitochondrial-dysfunction-neurodegenerative-disease)
• [Neuroinflammation Mechanisms](/mechanisms/neuroinflammation-mechanisms)

Related Genes/Proteins

• [CBS Gene](/genes/cbs) - Cystathionine beta-synthase
• [CSE Gene](/genes/cth) - Cystathionine gamma-lyase

Related Diseases

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Huntington's Disease](/diseases/huntingtons)

References